September 21, 2026 - ROTOP today joined employees, project partners, representatives of the planning and construction companies involved, and guests from government and industry for a symbolic groundbreaking ceremony marking the upcoming start of construction on its new CMO Center in Dresden-Rossendorf. Guests included Dirk Hilbert, Mayor of Dresden, and Regina Kraushaar, Saxony's State Minister for Infrastructure and Regional Development.

August 7, 2026 - A reunion with a long-standing companion: Saxon State Parliament member Thomas Schmidt visited our Radiopharmacy to learn about its development since its inauguration in 2020. The discussions focused on the future of radiopharmacy and nuclear medicine as well as the European framework for innovative diagnostic and therapeutic approaches.

April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.

March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.

January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.

August 15, 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions.